Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.

Tanja Stahl; Anita Badbaran; Nicolaus Kröger; Evgeny Klyuchnikov; Tatjana Zabelina; Silke Zeschke; Philippe Schafhausen; Waltraud Schultz; Svetlana Asenova; Anna Smirnova; Christine Wolschke; Francis Ayuketang Ayuk; Axel R. Zander; Boris Fehse; Ulrike Bacher

doi:10.3109/10428194.2010.508822

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.

Standard

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis. / Stahl, Tanja; Badbaran, Anita ; Kröger, Nicolaus ; Klyuchnikov, Evgeny; Zabelina, Tatjana; Zeschke, Silke; Schafhausen, Philippe; Schultz, Waltraud; Asenova, Svetlana; Smirnova, Anna; Wolschke, Christine ; Ayuketang Ayuk, Francis; Zander, Axel R.; Fehse, Boris; Bacher, Ulrike.

In: LEUKEMIA LYMPHOMA, Vol. 51, No. 10, 10, 01.10.2010, p. 1837-1843.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Stahl, T, Badbaran, A , Kröger, N , Klyuchnikov, E, Zabelina, T, Zeschke, S, Schafhausen, P, Schultz, W, Asenova, S, Smirnova, A, Wolschke, C , Ayuketang Ayuk, F, Zander, AR, Fehse, B & Bacher, U 2010, 'Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.', LEUKEMIA LYMPHOMA, vol. 51, no. 10, 10, pp. 1837-1843. https://doi.org/10.3109/10428194.2010.508822

APA

Stahl, T., Badbaran, A., Kröger, N., Klyuchnikov, E., Zabelina, T., Zeschke, S., Schafhausen, P., Schultz, W., Asenova, S., Smirnova, A., Wolschke, C., Ayuketang Ayuk, F., Zander, A. R., Fehse, B., & Bacher, U. (2010). Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis. LEUKEMIA LYMPHOMA, 51(10), 1837-1843. [10]. https://doi.org/10.3109/10428194.2010.508822

Vancouver

Stahl T, Badbaran A , Kröger N , Klyuchnikov E, Zabelina T, Zeschke S et al. Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis. LEUKEMIA LYMPHOMA. 2010 Oct 1;51(10):1837-1843. 10. https://doi.org/10.3109/10428194.2010.508822

Bibtex

@article{80c4e1e8ef614172883569a362138836,

title = "Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.",

abstract = "Considering the high relapse rates of AML after allogeneic hematopoietic stem cell transplant, research aims to improve post-transplant surveillance. To determine the value of peripheral blood (PB) for post-transplant minimal residual disease monitoring, we compared 38 PB and bone marrow (BM) sample pairs in 25 stem cell recipients with NPM1-mutated AML (12 males, 13 females, ages 21-73 years). NPM1A mutation levels and chimerism ratios were determined in non-separated BM/PB. We observed congruent results in 28/38 (74%). In 14/38 sample pairs (37%), BM and PB were negative for the NPM1A mutation. Fourteen sample pairs were positive in BM and PB, albeit at higher mutation levels in the BM in 11 cases (4- to 278-fold). Results were discordant in 10 cases (26%), with weakly positive mutation levels in the BM but negative levels in the PB. Cases with 0.2% NPM1A mutation level in BM were always positive in PB. Chimerism was concordant in BM and PB in 21/34 (62%) of sample pairs. In conclusion, MRD monitoring with qPCR for the NPM1 mutation and chimerism from non-separated PB contributes to surveillance in patients with AML in the post-transplant period, but even with highly sensitive qPCR there is a risk of failure to detect the mutation in PB.",

keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Young Adult, Disease-Free Survival, Mutation, Acute Disease, Bone Marrow metabolism, Hematopoietic Stem Cell Transplantation methods, Leukemia, Myeloid blood, Neoplasm, Residual diagnosis, Nuclear Proteins genetics, Polymerase Chain Reaction, Postoperative Period, Transplantation Chimera blood, Transplantation, Homologous, Adult, Humans, Male, Aged, Female, Middle Aged, Young Adult, Disease-Free Survival, Mutation, Acute Disease, Bone Marrow metabolism, Hematopoietic Stem Cell Transplantation methods, Leukemia, Myeloid blood, Neoplasm, Residual diagnosis, Nuclear Proteins genetics, Polymerase Chain Reaction, Postoperative Period, Transplantation Chimera blood, Transplantation, Homologous",

author = "Tanja Stahl and Anita Badbaran and Nicolaus Kr{\"o}ger and Evgeny Klyuchnikov and Tatjana Zabelina and Silke Zeschke and Philippe Schafhausen and Waltraud Schultz and Svetlana Asenova and Anna Smirnova and Christine Wolschke and {Ayuketang Ayuk}, Francis and Zander, {Axel R.} and Boris Fehse and Ulrike Bacher",

year = "2010",

month = oct,

day = "1",

doi = "10.3109/10428194.2010.508822",

language = "English",

volume = "51",

pages = "1837--1843",

journal = "LEUKEMIA LYMPHOMA",

issn = "1042-8194",

publisher = "informa healthcare",

number = "10",

}

RIS

TY - JOUR

T1 - Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.

AU - Stahl, Tanja

AU - Badbaran, Anita

AU - Kröger, Nicolaus

AU - Klyuchnikov, Evgeny

AU - Zabelina, Tatjana

AU - Zeschke, Silke

AU - Schafhausen, Philippe

AU - Schultz, Waltraud

AU - Asenova, Svetlana

AU - Smirnova, Anna

AU - Wolschke, Christine

AU - Ayuketang Ayuk, Francis

AU - Zander, Axel R.

AU - Fehse, Boris

AU - Bacher, Ulrike

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Considering the high relapse rates of AML after allogeneic hematopoietic stem cell transplant, research aims to improve post-transplant surveillance. To determine the value of peripheral blood (PB) for post-transplant minimal residual disease monitoring, we compared 38 PB and bone marrow (BM) sample pairs in 25 stem cell recipients with NPM1-mutated AML (12 males, 13 females, ages 21-73 years). NPM1A mutation levels and chimerism ratios were determined in non-separated BM/PB. We observed congruent results in 28/38 (74%). In 14/38 sample pairs (37%), BM and PB were negative for the NPM1A mutation. Fourteen sample pairs were positive in BM and PB, albeit at higher mutation levels in the BM in 11 cases (4- to 278-fold). Results were discordant in 10 cases (26%), with weakly positive mutation levels in the BM but negative levels in the PB. Cases with 0.2% NPM1A mutation level in BM were always positive in PB. Chimerism was concordant in BM and PB in 21/34 (62%) of sample pairs. In conclusion, MRD monitoring with qPCR for the NPM1 mutation and chimerism from non-separated PB contributes to surveillance in patients with AML in the post-transplant period, but even with highly sensitive qPCR there is a risk of failure to detect the mutation in PB.

AB - Considering the high relapse rates of AML after allogeneic hematopoietic stem cell transplant, research aims to improve post-transplant surveillance. To determine the value of peripheral blood (PB) for post-transplant minimal residual disease monitoring, we compared 38 PB and bone marrow (BM) sample pairs in 25 stem cell recipients with NPM1-mutated AML (12 males, 13 females, ages 21-73 years). NPM1A mutation levels and chimerism ratios were determined in non-separated BM/PB. We observed congruent results in 28/38 (74%). In 14/38 sample pairs (37%), BM and PB were negative for the NPM1A mutation. Fourteen sample pairs were positive in BM and PB, albeit at higher mutation levels in the BM in 11 cases (4- to 278-fold). Results were discordant in 10 cases (26%), with weakly positive mutation levels in the BM but negative levels in the PB. Cases with 0.2% NPM1A mutation level in BM were always positive in PB. Chimerism was concordant in BM and PB in 21/34 (62%) of sample pairs. In conclusion, MRD monitoring with qPCR for the NPM1 mutation and chimerism from non-separated PB contributes to surveillance in patients with AML in the post-transplant period, but even with highly sensitive qPCR there is a risk of failure to detect the mutation in PB.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Young Adult

KW - Disease-Free Survival

KW - Mutation

KW - Acute Disease

KW - Bone Marrow metabolism

KW - Hematopoietic Stem Cell Transplantation methods

KW - Leukemia, Myeloid blood

KW - Neoplasm, Residual diagnosis

KW - Nuclear Proteins genetics

KW - Polymerase Chain Reaction

KW - Postoperative Period

KW - Transplantation Chimera blood

KW - Transplantation, Homologous

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Young Adult

KW - Disease-Free Survival

KW - Mutation

KW - Acute Disease

KW - Bone Marrow metabolism

KW - Hematopoietic Stem Cell Transplantation methods

KW - Leukemia, Myeloid blood

KW - Neoplasm, Residual diagnosis

KW - Nuclear Proteins genetics

KW - Polymerase Chain Reaction

KW - Postoperative Period

KW - Transplantation Chimera blood

KW - Transplantation, Homologous

U2 - 10.3109/10428194.2010.508822

DO - 10.3109/10428194.2010.508822

M3 - SCORING: Journal article

C2 - 20849383

VL - 51

SP - 1837

EP - 1843

JO - LEUKEMIA LYMPHOMA

JF - LEUKEMIA LYMPHOMA

SN - 1042-8194

IS - 10

M1 - 10

ER -